Table 1. HGF/Met pathway inhibitors in human clinical trials.
Status of clinical trials uses terms as defined at ClinicalTrials.gov
| Drug | Design | Phase | Status | Patient population | Combinations | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| Rilotumumab (AMG 102) | Safety | Ib/II | Active | NSCLC1 | Cisplatin/Etoposide | NCT00791154 |
| Safety/Efficacy | I/II | Active | mCRC2, wt KRAS | Panitumumab | NCT00788957 | |
| Safety/Efficacy | I/II | Active | CRPC3 | Mitoxantrone/Prednisone | NCT00770848 | |
| Safety/Efficacy | II | Active | RCC4 | NCT00422019 | ||
| Safety/Efficacy | II | Active | Advanced Malignant Glioma | NCT00427440 | ||
| Safety/Efficacy | I/II | Active | Locally Advanced/Metastatic EGJ Adenocarcinoma5 | ECXx | NCT00719550 | |
| Safety | I/II | Recruiting | NSCLC | Erlotinib | NCT01233687 | |
| Efficacy/Safety | II | Recruiting | Recurrent Malignant Glioma | Avastin | NCT01113398 | |
| Efficacy | II | Recruiting | Advanced Gastroesophageal Adenocarcinoma | FOLFOXxx | NCT01443065 | |
| Safety | II | Recruiting | Persistent/Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | NCT01039207 | ||
| Onartuzumab (MetMAb) | Safety | I | Completed | Advanced Solid Malignancies | Avastin | NCT01068977 |
| Efficacy | II | Active | NSCLC | Erlotinib | NCT00854308 | |
| Efficacy | II | Recruiting | Metastatic/Recurrent, triple-negative Breast Cancer | Bevacizumab and Paclitaxel | NCT01186991 | |
| Efficacy | II | Recruiting | mCRC | FOLFOX/Bevacizumab | NCT01418222 | |
| Safety/Efficacy | III | Not yet recruiting | NSCLC (Met diagnostic-positive) | Erlotinib | NCT01456325 | |
| Ficlatuzumab (AV-299) | Safety/Efficacy | I | Terminated | Glioblastoma | NCT01189513 | |
| Safety/Tolerability | I | Active | Advanced/Metastatic Solid Malignancies | NCT00969410 | ||
| Safety/Efficacy | I/II | Active | NSCLC | Gefitinib | NCT01039948 | |
| Safety | I | Active | Relapsed/Refractory Solid Malignancies | Erlotinib | NCT00725634 | |
|
TAK-701 AMG 337 AMG 208 Tivatinib (ARQ 197) |
Safety/Tolerability/PK | I | Active | Non-Hematologic Malignancies | NCT00831896 | |
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT01253707 | ||
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT00813384 | ||
| Safety/Efficacy | I | Completed | Advanced Solid Malignancies | NCT00612209 | ||
| Bio-availability | I | Completed | Advanced Solid Malignancies | NCT01149720 | ||
| Safety/Efficacy | II | Active | GC6 | NCT01152645 | ||
| Safety/Efficacy | I/II | Recruiting | CRC, wt KRAS | Irinotecan/Cetuximab | NCT01075048 | |
| Safety/Efficacy | II | Recruiting | Advanced/Metastatic NSCLC, KRAS mutation + | Erlotinib | NCT01395758 | |
| Safety | I | Completed | Advanced Solid Malignancies | Gemcitabine | NCT00874042 | |
| Safety/Efficacy | II | Active | HCC7 | NCT00988741 | ||
| Safety | I | Recruiting | Advanced Solid Malignancies | Sorafenib | NCT00827177 | |
| PK# | I | Completed | Healthy volunter | NCT00651638 | ||
| Safety | I | Active | NSCLC | Erlotinib | NCT01251796 | |
| Safety | I | Active | Advanced/Recurrent NSCLC | Erlotinib | NCT01069757 | |
| Safety/Efficacy | III | Recruiting | Non Squamous NSCLC | Erlotinib | NCT01244191 | |
| Safety/Tolerability | I | Completed | Metastatic Solid Malignancies | NCT00302172 | ||
| Efficacy | II | Completed | Unresectable Locally Advanced/Metastatic Pancreatic Adenocarcinoma | Gemcitabine | NCT00558207 | |
| Safety/Efficacy | I | Completed | Advanced Solid Malignancies | Erlotinib | NCT00612703 | |
| Efficacy | II | Withdrawn | Locally Advanced/Metastatic GC | Oxaliplatin/Capecitabine/Irinotecan | NCT01070290 | |
| Safety | I | Recruiting | Advanced Solid Malignancies | Pazopanib | NCT01468922 | |
| Safety | I | Active | HCC (Cirrhotic patients) | Erlotinib | NCT00802555 | |
| Efficacy | II | Completed | Advanced/Metastatic NSCLC | Erlotinib | NCT00777309 | |
| PK | I | Completed | Healthy Volunter | NCT00658554 | ||
| Safety/Tolerability | I | Active | Advanced Solid/Recurrent Malignancies | NCT00609921 | ||
| Efficacy | III | Recruiting | Advanced/Metastatic Non Squamous NSCLC wt EGFR | Erlotinib | NCT01377376 | |
| Safety/Efficacy | II | Active | Refractory Germ Cell Tumors | NCT01055067 | ||
| Safety/Efficacy | I/II | Recruiting | Subjects previously enrolled in other ARQ 197 study | NCT01178411 | ||
| Safety/Efficacy | II | Completed | MiT8 associated with RCC9/ASPS10/CCS11 | NCT00557609 | ||
| Safety/Efficacy | II | Not yet recruiting | Relapsed Multiple Myeloma | NCT01447914 | ||
| BMS777607 | Safety/Efficacy | I/II | Completed | Advanced/Metastatic Solid SCCHN12, PRCC13 Malignancies, CRPC, | NCT00605618 | |
| E7050 | Efficacy | I/II | Recruiting | Advanced Solid Malignancies, Glioblastoma, Unresectable Stage III/IV Melanoma | E7080 | NCT01433991 |
|
EMD 1214063 EMD1204831 Foretinib (GSK1363089) |
Safety | I | Recruiting | Advanced Solid Malignancies | NCT01014936 | |
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT01110083 | ||
| Safety/Efficacy | II | Completed | Recurrent/Metastatic SCCHN | NCT00725764 | ||
| Safety | I | Completed | Advanced Solid Malignancies | NCT00743067 | ||
| Safety/Efficacy | II | Completed | mGC | NCT00725712 | ||
| Bio-availability | I | Completed | Advanced Solid Malignancies | NCT00742261 | ||
| Safety/Efficacy | I | Active | HCC | NCT00920192 | ||
| Safety/Efficacy | II | Active | PRCC | NCT00726323 | ||
| Safety/Efficacy | I/II | Recruiting | Locally Advanced/Metastatic NSCLC | Erlotinib | NCT01068587 | |
| Safety/Efficacy | I/II | Recruiting | HER2 Over-Expressing Metastatic Breast Cancer | Lapatinib | NCT01138384 | |
| Safety/Efficacy | II | Recruiting | ER+/PR+and HER2-Brest Cancer 14 | NCT01147484 | ||
|
INCB28060 LY2801653 MK8033 |
Safety/Tolerability | I | Recruiting | Advanced Solid Malignancies | NCT01072266 | |
| Safety/Tolerability | I | Recruiting | Advanced and/or Metastatic Cancer | NCT01285037 | ||
| Safety | I | Completed | Advanced Solid Malignancies | Omeprazole | NCT00559182 | |
| Safety/Efficacy | I/II | Not yet recruiting | Locally Advanced/Metastatic Solid Malignancies, GC | Ciplastin/Capecitabine | NCT01355302 | |
| Safety/Efficacy | I | Completed | Advanced Solid Malignancies | NCT00921869 | ||
| Safety/Efficacy | I/II | Recruiting | Platinum Resistant, Recurrent/Metastatic SCCHN | Cetuximab | NCT01332266 | |
| Safety/Efficacy | I/II | Recruiting | Locally Advanced/Metastatic HCC | Sorafenib | NCT01271504 | |
| Safety/Efficacy | I | Not yet recruiting | Advanced Solid Malignancies | NCT01428141 | ||
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT00869895 | ||
| Amuvatinib (MP470) | Safety | I | Completed | Advanced Solid Malignancies | NCT00894894 | |
| Safety/Efficacy | I | Completed | Advanced Solid Malignancies | Topotecan/Docetaxel/Erlotinib/Paclitaxel/Carboplatin/Carboplatin/Etoposide | NCT00881166 | |
| Efficacy | II | Recruiting | SCLC | Platinum/Etoposide | NCT01357395 | |
| Safety/PK/PD* | NA | Terminated | Metastatic Solid Malignancies/Lymphoma | NCT00504205 | ||
| MGCD265 | Safety/Efficacy | I/II | Recruiting | Advanced Malignancies/NSCLC | Erlotinib/Docetaxel | NCT00975767 |
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT00697632 | ||
| Safety | I | Completed | Advanced Solid Malignancies | NCT00679133 | ||
| MK-2461 | Safety/Efficacy | I/II | Completed | Advanced Solid Malignancies | NCT00496353 | |
| Safety | I | Completed | Advanced Solid Malignancies | NCT00518739 | ||
|
Crizotinib PF02341066 |
PK | I | Not yet recruiting | Subjects With Impaired Renal Function | NCT01419041 | |
| Safety/PK/PD | I | Not yet recruiting | Advanced Solid Malignancies | Axitinib/Sunitinib/Bevacizumab/Sorafenib | NCT01441388 | |
| Safety/Efficacy | I | Recruiting | ALK+ Tumors15 | NCT01121588 | ||
| PK | I | Completed | Japanese Healthy Male Volunteers | NCT01250730 | ||
| PK | I | Completed | Healthy Volunter | NCT01297595 | ||
| Safety/Efficacy | I/II | Recruiting | NSCLC | Erlotinib | NCT00965731 | |
| PK | I | Completed | Healthy Volunter | NCT01168934 | ||
| Safety/Efficacy | I | Recruiting | NSCLC | PF 00299804 | NCT01121575 | |
| PK^ | I | Completed | Healthy Male Volunter | NCT01082380 | ||
| PK | I | Completed | Healthy Volunter | Ketoconazole | NCT01149785 | |
| PK | I | Completed | Healthy Volunter | Rifampin | NCT01147055 | |
| PK | I | Completed | Healthy Volunter | NCT01154218 | ||
| Safety | I | Recruiting | Advanced Solid Malignancies | NCT00585195 | ||
| Safety/Efficacy | III | Recruiting | NSCLC, ALK+ | Pemetrexed/Docetaxel | NCT00932893 | |
| Safety/PK | I/II | Recruiting | Relapsed/Refractory Solid Malignancies or Anaplastic Large Cell Lymphoma (Young Population) | NCT00939770 | ||
| Safety/Efficacy | II | Recruiting | NSCLC, ALK+ | NCT00932451 | ||
| PF02341066 | Bio availability | I | Completed | Healthy Volunter | NCT00939731 | |
| Taste Assessment | I | Completed | Healthy Volunter | NCT01125904 | ||
| Safety | I | Recruiting | NSCLC | PF 00299804 | NCT01441128 | |
| Obtain tissue | Recruiting | NSCLC, ALK+ | NCT01300429 | |||
| Safety/Efficacy | III | Recruiting | Recurrent/Metastatic Non Squamous Cell Carcinoma of the Lung ALK + | NCT01154140 | ||
| PF04217903 | Safety/Efficacy | I | Completed | Advanced Solid Malignancies | NCT00706355 | |
| Cabozantinib (XL184) | Safety/Efficacy | II | Not yet recruiting | mCRPC | NCT01428219 | |
| Safety/Efficacy | II | Not yet recruiting | Carcinoid/Pancreatic Neuroendocrine Tumor | NCT01466036 | ||
| Efficacy | II | Recruiting | Brest Cancer, ER+/PR+and HER2- | NCT01441947 | ||
| Safety/Efficacy | I | Recruiting | mCRPC | NCT01347788 | ||
| Safety | I | Active | Advanced Solid Malignancies | NCT00215605 | ||
| Safety/Efficacy | II | Recruiting | Advanced Solid Malignancies | NCT00940225 | ||
| Efficacy | III | Active | MTC16 | NCT00704730 | ||
| Safety/Efficacy | II | Active | Glioblastoma Multiforme | NCT00704288 | ||
| Safety/Efficacy | I/II | Active | NSCLC | Erlotinib | NCT00596648 | |
| PK | I | Active | Advanced Solid Malignancies | Rosiglitazone | NCT01100619 | |
| Safety | I | Active | Glioblastoma | Temozolomide/Radiation Therapy | NCT00960492 | |
| Safety/Efficacy | II | Active | Grade IV AstrocyticTumor | NCT01068782 | ||
| Safety | I | Completed | Advanced/Metastatic Solid Malignancies (Japanese | NCT01018745 |
#
PK: Pharmacokinetics
*
PD: Pharmacodymanics
^
[14C]PF 02341066
1
NSCLC: Non Small Cell Lung Cancer
2
CRC: Colorectal Cancer
3
CRPC: Castrate Resistant Prostate Cancer
4
RCC: Renal Cell Carcinoma
5
EGJ: Gastric or Esophagogastric Junction adenocarcinoma
6
GC: Gastic Cancer
7
HCC: Hepatocellular Carcinoma
8
MiT: Microphthalmia transcription factor associated Tumors
9
RCC: Renal Cell Carcinoma
10
ASPS: Alveolar Soft Part Sarcoma
11
CCS: Clear Cell Sarcoma
12
PRCC: Papillary Renal-Cell Carcinoma
13
SCCHN: Squamous Cell Carcinoma for the Head and Neck 14
14
ER+/PR+and HER2- Brest Cancer: Estrogen-receptor- positive/Progesterone-recepto r-positive and Human Epidermal Growth Factor Receptor 2 negative Breast Cancer
15
ALK: Anaplastic Lymphoma Kinase
16
MTC: Metastatic Medullary Thyroid Cancer
x
ECX: Capecitabine/Epirubicin/Cisplatin
xx
FOLFOX: Oxaliplatin/Folinic Acid/5-fluoro-uracil